Ipsen extended its 18-month dealmaking streak, lining up an antibody-drug conjugate from Shanghai-based Simcere Zaiming.
Paris-based Ipsen will pay $45 million upfront for access to an antibody-drug conjugate outside of Greater China, according to a ...
↧